Finally, activating pathogenic variants in RAS genes (HRAS, KRAS, NRAS) have been identified in RET-negative sporadic MTC, often linked with a more indolent course compared to RET-driven tumors. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.